Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Review Article

Which can Predict the Outcome of Antidepressants: Metabolic Genes or Pharmacodynamic Genes?

Author(s): Nan Zheng*, Mengxi Niu, Yannan Zang, Hongyan Zhuang, Fei Jia, Shuang Bao and Shanshan Liu

Volume 24, Issue 7, 2023

Published on: 18 September, 2023

Page: [525 - 535] Pages: 11

DOI: 10.2174/1389200224666230907093349

Price: $65

Open Access Journals Promotions 2
Abstract

Drug therapy is the primary modality for depression; however, its outcome is often unpredictable, ranging from beneficial effects to serious adverse effects. Genetic variations in drug metabolizing enzymes and pharmacodynamic molecules are responsible for a considerable proportion of interindividual differences in the effectiveness and toxicity of antidepressants. For the improvement in the use of antidepressants, the focus is mainly on personalized treatment emphasizing interindividual differences in genes. This study provides a comprehensive review of the literature on the clinical applications of pharmacogenomics for antidepressant therapy. The polymorphisms of metabolizing enzymes (CYP2D6, CYP2C19, and others) governing the pharmacokinetic behavior of drugs are potential predictors of side effects or treatment failure with medications and there are good pharmacogenetic clinical recommendations for a wide selection of psychopharmacological agents based on functional diplotypes of CYP2C19 and CYP2D6. The relationship between pharmacodynamic genes, including FKBP5, SLC6A4, BDNF, ABCB1, HTR1A, and HTR2A, and clinical outcomes varies in different races. Receptors that are currently used as drug targets for antidepressant drugs are evolutionarily conserved to a higher extent than genes encoding drug metabolism, and the actionability of pharmacodynamic-related genotyping is currently still questionable. The limited availability of largescale, long-term clinical studies on different races and medications currently impedes the implementation of pharmacogenomics in antidepressant treatment. The use of pharmacokinetic and pharmacodynamic modeling, and therapeutic drug monitoring combined with genetic, somatic, dietary, and environmental factors represents a promising avenue for improving the precision and effectiveness of antidepressant therapy.

Keywords: Pharmacogenetics, antidepressants, efficacy, adverse drug reactions, genotype, pharmacodynamics, metabolic enzyme.

Graphical Abstract
[1]
Moitra, M.; Santomauro, D.; Collins, P.Y.; Vos, T.; Whiteford, H.; Saxena, S.; Ferrari, A.J. The global gap in treatment coverage for major depressive disorder in 84 countries from 2000–2019: A systematic review and Bayesian meta-regression analysis. PLoS Med., 2022, 19(2), e1003901.
[http://dx.doi.org/10.1371/journal.pmed.1003901] [PMID: 35167593]
[2]
Vos, T.; Lim, S.S.; Abbafati, C.; Abbas, K.M.; Abbasi, M.; Abbasifard, M.; Abbasi-Kangevari, M.; Abbastabar, H.; Abd-Allah, F.; Abdelalim, A.; Abdollahi, M.; Abdollahpour, I.; Abolhassani, H.; Aboyans, V.; Abrams, E.M.; Abreu, L.G.; Abrigo, M.R.M.; Abu-Raddad, L.J.; Abush-ouk, A.I.; Acebedo, A.; Ackerman, I.N.; Adabi, M.; Adamu, A.A.; Adebayo, O.M.; Adekanmbi, V.; Adelson, J.D.; Adetokunboh, O.O.; Ad-ham, D.; Afshari, M.; Afshin, A.; Agardh, E.E.; Agarwal, G.; Agesa, K.M.; Aghaali, M.; Aghamir, S.M.K.; Agrawal, A.; Ahmad, T.; Ahmadi, A.; Ahmadi, M.; Ahmadieh, H.; Ahmadpour, E.; Akalu, T.Y.; Akinyemi, R.O.; Akinyemiju, T.; Akombi, B.; Al-Aly, Z.; Alam, K.; Alam, N.; Alam, S.; Alam, T.; Alanzi, T.M.; Albertson, S.B.; Alcalde-Rabanal, J.E.; Alema, N.M.; Ali, M.; Ali, S.; Alicandro, G.; Alijanzadeh, M.; Alinia, C.; Alipour, V.; Aljunid, S.M.; Alla, F.; Allebeck, P.; Almasi-Hashiani, A.; Alonso, J.; Al-Raddadi, R.M.; Altirkawi, K.A.; Alvis-Guzman, N.; Alvis-Zakzuk, N.J.; Amini, S.; Amini-Rarani, M.; Aminorroaya, A.; Amiri, F.; Amit, A.M.L.; Amugsi, D.A.; Amul, G.G.H.; Anderlini, D.; Andrei, C.L.; Andrei, T.; Anjomshoa, M.; Ansari, F.; Ansari, I.; Ansari-Moghaddam, A.; Antonio, C.A.T.; Antony, C.M.; Antriyandarti, E.; Anvari, D.; Anwer, R.; Arabloo, J.; Arab-Zozani, M.; Aravkin, A.Y.; Ariani, F.; Ärnlöv, J.; Aryal, K.K.; Arzani, A.; Asadi-Aliabadi, M.; Asa-di-Pooya, A.A.; Asghari, B.; Ashbaugh, C.; Atnafu, D.D.; Atre, S.R.; Ausloos, F.; Ausloos, M.; Ayala Quintanilla, B.P.; Ayano, G.; Ayanore, M.A.; Aynalem, Y.A.; Azari, S.; Azarian, G.; Azene, Z.N.; Babaee, E.; Badawi, A.; Bagherzadeh, M.; Bakhshaei, M.H.; Bakhtiari, A.; Bala-krishnan, S.; Balalla, S.; Balassyano, S.; Banach, M.; Banik, P.C.; Bannick, M.S.; Bante, A.B.; Baraki, A.G.; Barboza, M.A.; Barker-Collo, S.L.; Barthelemy, C.M.; Barua, L.; Barzegar, A.; Basu, S.; Baune, B.T.; Bayati, M.; Bazmandegan, G.; Bedi, N.; Beghi, E.; Béjot, Y.; Bello, A.K.; Bender, R.G.; Bennett, D.A.; Bennitt, F.B.; Bensenor, I.M.; Benziger, C.P.; Berhe, K.; Bernabe, E.; Bertolacci, G.J.; Bhageerathy, R.; Bhala, N.; Bhandari, D.; Bhardwaj, P.; Bhattacharyya, K.; Bhutta, Z.A.; Bibi, S.; Biehl, M.H.; Bikbov, B.; Bin Sayeed, M.S.; Biondi, A.; Biri-hane, B.M.; Bisanzio, D.; Bisignano, C.; Biswas, R.K.; Bohlouli, S.; Bohluli, M.; Bolla, S.R.R.; Boloor, A.; Boon-Dooley, A.S.; Borges, G.; Borzì, A.M.; Bourne, R.; Brady, O.J.; Brauer, M.; Brayne, C.; Breitborde, N.J.K.; Brenner, H.; Briant, P.S.; Briggs, A.M.; Briko, N.I.; Britton, G.B.; Bryazka, D.; Buchbinder, R.; Bumgarner, B.R.; Busse, R.; Butt, Z.A.; Caetano dos Santos, F.L.; Cámera, L.L.A.A.; Campos-Nonato, I.R.; Car, J.; Cárdenas, R.; Carreras, G.; Carrero, J.J.; Carvalho, F.; Castaldelli-Maia, J.M.; Castañeda-Orjuela, C.A.; Castelpietra, G.; Castle, C.D.; Castro, F.; Catalá-López, F.; Causey, K.; Cederroth, C.R.; Cercy, K.M.; Cerin, E.; Chandan, J.S.; Chang, A.R.; Charlson, F.J.; Chattu, V.K.; Chaturvedi, S.; Chimed-Ochir, O.; Chin, K.L.; Cho, D.Y.; Christensen, H.; Chu, D-T.; Chung, M.T.; Cicuttini, F.M.; Ciobanu, L.G.; Ci-rillo, M.; Collins, E.L.; Compton, K.; Conti, S.; Cortesi, P.A.; Costa, V.M.; Cousin, E.; Cowden, R.G.; Cowie, B.C.; Cromwell, E.A.; Cross, D.H.; Crowe, C.S.; Cruz, J.A.; Cunningham, M.; Dahlawi, S.M.A.; Damiani, G.; Dandona, L.; Dandona, R.; Darwesh, A.M.; Daryani, A.; Das, J.K.; Das Gupta, R. das Neves, J.; Dávila-Cervantes, C.A.; Davletov, K.; De Leo, D.; Dean, F.E.; DeCleene, N.K.; Deen, A.; Degenhardt, L.; Dellavalle, R.P.; Demeke, F.M.; Demsie, D.G.; Denova-Gutiérrez, E.; Dereje, N.D.; Dervenis, N.; Desai, R.; Desalew, A.; Dessie, G.A.; Dhar-maratne, S.D.; Dhungana, G.P.; Dianatinasab, M.; Diaz, D.; Dibaji Forooshani, Z.S.; Dingels, Z.V.; Dirac, M.A.; Djalalinia, S.; Do, H.T.; Dokova, K.; Dorostkar, F.; Doshi, C.P.; Doshmangir, L.; Douiri, A.; Doxey, M.C.; Driscoll, T.R.; Dunachie, S.J.; Duncan, B.B.; Duraes, A.R.; Eagan, A.W.; Ebrahimi Kalan, M.; Edvardsson, D.; Ehrlich, J.R.; El Nahas, N.; El Sayed, I.; El Tantawi, M.; Elbarazi, I.; Elgendy, I.Y.; El-habashy, H.R.; El-Jaafary, S.I.; Elyazar, I.R.F.; Emamian, M.H.; Emmons-Bell, S.; Erskine, H.E.; Eshrati, B.; Eskandarieh, S.; Esmaeilnejad, S.; Esmaeilzadeh, F.; Esteghamati, A.; Estep, K.; Etemadi, A.; Etisso, A.E.; Farahmand, M.; Faraj, A.; Fareed, M.; Faridnia, R.; Farinha, C.S.S.; Farioli, A.; Faro, A.; Faruque, M.; Farzadfar, F.; Fattahi, N.; Fazlzadeh, M.; Feigin, V.L.; Feldman, R.; Fereshtehnejad, S-M.; Fer-nandes, E.; Ferrari, A.J.; Ferreira, M.L.; Filip, I.; Fischer, F.; Fisher, J.L.; Fitzgerald, R.; Flohr, C.; Flor, L.S.; Foigt, N.A.; Folayan, M.O.; Force, L.M.; Fornari, C.; Foroutan, M.; Fox, J.T.; Freitas, M.; Fu, W.; Fukumoto, T.; Furtado, J.M.; Gad, M.M.; Gakidou, E.; Galles, N.C.; Gallus, S.; Gamkrelidze, A.; Garcia-Basteiro, A.L.; Gardner, W.M.; Geberemariyam, B.S.; Gebrehiwot, A.M.; Gebremedhin, K.B.; Gebres-lassie, A.A.A.A.; Gershberg Hayoon, A.; Gething, P.W.; Ghadimi, M.; Ghadiri, K.; Ghafourifard, M.; Ghajar, A.; Ghamari, F.; Ghashghaee, A.; Ghiasvand, H.; Ghith, N.; Gholamian, A.; Gilani, S.A.; Gill, P.S.; Gitimoghaddam, M.; Giussani, G.; Goli, S.; Gomez, R.S.; Gopalani, S.V.; Gorini, G.; Gorman, T.M.; Gottlich, H.C.; Goudarzi, H.; Goulart, A.C.; Goulart, B.N.G.; Grada, A.; Grivna, M.; Grosso, G.; Gubari, M.I.M.; Gugnani, H.C.; Guimaraes, A.L.S.; Guimarães, R.A.; Guled, R.A.; Guo, G.; Guo, Y.; Gupta, R.; Haagsma, J.A.; Haddock, B.; Hafezi-Nejad, N.; Hafiz, A.; Hagins, H.; Haile, L.M.; Hall, B.J.; Halvaei, I.; Hamadeh, R.R.; Hamagharib Abdullah, K.; Hamilton, E.B.; Han, C.; Han, H.; Hankey, G.J.; Haro, J.M.; Harvey, J.D.; Hasaballah, A.I.; Hasanzadeh, A.; Hashemian, M.; Hassanipour, S.; Hassankhani, H.; Havmoeller, R.J.; Hay, R.J.; Hay, S.I.; Hayat, K.; Heidari, B.; Heidari, G.; Heidari-Soureshjani, R.; Hendrie, D.; Henrikson, H.J.; Henry, N.J.; Herteliu, C.; Heydarpour, F.; Hird, T.R.; Hoek, H.W.; Hole, M.K.; Holla, R.; Hoogar, P.; Hosgood, H.D.; Hosseinzadeh, M.; Hostiuc, M.; Hostiuc, S.; Househ, M.; Hoy, D.G.; Hsairi, M.; Hsieh, V.C.; Hu, G.; Huda, T.M.; Hugo, F.N.; Huynh, C.K.; Hwang, B-F.; Iannucci, V.C.; Ibitoye, S.E.; Ikuta, K.S.; Ilesanmi, O.S.; Ilic, I.M.; Ilic, M.D.; Inbaraj, L.R.; Ippolito, H.; Irvani, S.S.N.; Islam, M.M.; Islam, M.M.; Islam, S.M.S.; Islami, F.; Iso, H.; Ivers, R.Q.; Iwu, C.C.D.; Iyamu, I.O.; Jaafari, J.; Jacobsen, K.H.; Jadidi-Niaragh, F.; Jafari, H.; Jafarinia, M.; Jahagirdar, D.; Jahani, M.A.; Jahanmehr, N.; Jakovljevic, M.; Jalali, A.; Jalilian, F.; James, S.L.; Janjani, H.; Janodia, M.D.; Jayatilleke, A.U.; Jeemon, P.; Jenabi, E.; Jha, R.P.; Jha, V.; Ji, J.S.; Jia, P.; John, O.; John-Akinola, Y.O.; Johnson, C.O.; Johnson, S.C.; Jonas, J.B.; Joo, T.; Joshi, A.; Jozwiak, J.J.; Jürisson, M.; Kabir, A.; Kabir, Z.; Kalani, H.; Kalani, R.; Kalankesh, L.R.; Kalhor, R.; Kamiab, Z.; Kanchan, T.; Karami Matin, B.; Karch, A.; Karim, M.A.; Karimi, S.E.; Kassa, G.M.; Kassebaum, N.J.; Katikireddi, S.V.; Kawakami, N.; Kayode, G.A.; Keddie, S.H.; Keller, C.; Kereselidze, M.; Khafaie, M.A.; Khalid, N.; Khan, M.; Khatab, K.; Khater, M.M.; Khatib, M.N.; Khayamzadeh, M.; Khodayari, M.T.; Khund-kar, R.; Kianipour, N.; Kieling, C.; Kim, D.; Kim, Y-E.; Kim, Y.J.; Kimokoti, R.W.; Kisa, A.; Kisa, S.; Kissimova-Skarbek, K.; Kivimäki, M.; Kneib, C.J.; Knudsen, A.K.S.; Kocarnik, J.M.; Kolola, T.; Kopec, J.A.; Kosen, S.; Koul, P.A.; Koyanagi, A.; Kravchenko, M.A.; Krishan, K.; Krohn, K.J.; Kuate Defo, B.; Kucuk Bicer, B.; Kumar, G.A.; Kumar, M.; Kumar, P.; Kumar, V.; Kumaresh, G.; Kurmi, O.P.; Kusuma, D.; Kyu, H.H.; La Vecchia, C.; Lacey, B.; Lal, D.K.; Lalloo, R.; Lam, J.O.; Lami, F.H.; Landires, I.; Lang, J.J.; Lansingh, V.C.; Larson, S.L.; Larsson, A.O.; Lasrado, S.; Lassi, Z.S.; Lau, K.M-M.; Lavados, P.M.; Lazarus, J.V.; Ledesma, J.R.; Lee, P.H.; Lee, S.W.H.; LeGrand, K.E.; Leigh, J.; Leonardi, M.; Lescinsky, H.; Leung, J.; Levi, M.; Lewington, S.; Li, S.; Lim, L-L.; Lin, C.; Lin, R-T.; Linehan, C.; Linn, S.; Liu, H-C.; Liu, S.; Liu, Z.; Looker, K.J.; Lopez, A.D.; Lopukhov, P.D.; Lorkowski, S.; Lotufo, P.A.; Lucas, T.C.D.; Lugo, A.; Lunevicius, R.; Lyons, R.A.; Ma, J.; MacLachlan, J.H.; Maddison, E.R.; Maddison, R.; Madotto, F.; Mahasha, P.W.; Mai, H.T.; Majeed, A.; Maled, V.; Maleki, S.; Malekzadeh, R.; Malta, D.C.; Mamun, A.A.; Manafi, A.; Manafi, N.; Manguerra, H.; Mansouri, B.; Mansournia, M.A.; Mantilla Herrera, A.M.; Maravilla, J.C.; Marks, A.; Martins-Melo, F.R.; Martopullo, I.; Masoumi, S.Z.; Massano, J.; Massenburg, B.B.; Mathur, M.R.; Maulik, P.K.; McAlinden, C.; McGrath, J.J.; McKee, M.; Mehndiratta, M.M.; Mehri, F.; Mehta, K.M.; Meitei, W.B.; Memiah, P.T.N.; Mendoza, W.; Menezes, R.G.; Mengesha, E.W.; Mengesha, M.B.; Mereke, A.; Meretoja, A.; Meretoja, T.J.; Mestrovic, T.; Miazgowski, B.; Miazgowski, T.; Michalek, I.M.; Mihretie, K.M.; Miller, T.R.; Mills, E.J.; Mirica, A.; Mirrakhimov, E.M.; Mirzaei, H.; Mirzaei, M.; Mirzaei-Alavijeh, M.; Mis-ganaw, A.T.; Mithra, P.; Moazen, B.; Moghadaszadeh, M.; Mohamadi, E.; Mohammad, D.K.; Mohammad, Y.; Mohammad Gholi Mezerji, N.; Mohammadian-Hafshejani, A.; Mohammadifard, N.; Mohammadpourhodki, R.; Mohammed, S.; Mokdad, A.H.; Molokhia, M.; Momen, N.C.; Monasta, L.; Mondello, S.; Mooney, M.D.; Moosazadeh, M.; Moradi, G.; Moradi, M.; Moradi-Lakeh, M.; Moradzadeh, R.; Moraga, P.; Morales, L.; Morawska, L.; Moreno Velásquez, I.; Morgado-da-Costa, J.; Morrison, S.D.; Mosser, J.F.; Mouodi, S.; Mousavi, S.M.; Mousavi Khaneghah, A.; Mueller, U.O.; Munro, S.B.; Muriithi, M.K.; Musa, K.I.; Muthupandian, S.; Naderi, M.; Nagarajan, A.J.; Nagel, G.; Naghshta-brizi, B.; Nair, S.; Nandi, A.K.; Nangia, V.; Nansseu, J.R.; Nayak, V.C.; Nazari, J.; Negoi, I.; Negoi, R.I.; Netsere, H.B.N.; Ngunjiri, J.W.; Ngu-yen, C.T.; Nguyen, J.; Nguyen, M.; Nguyen, M.; Nichols, E.; Nigatu, D.; Nigatu, Y.T.; Nikbakhsh, R.; Nixon, M.R.; Nnaji, C.A.; Nomura, S.; Norrving, B.; Noubiap, J.J.; Nowak, C.; Nunez-Samudio, V.; Oţoiu, A.; Oancea, B.; Odell, C.M.; Ogbo, F.A.; Oh, I-H.; Okunga, E.W.; Oladna-bi, M.; Olagunju, A.T.; Olusanya, B.O.; Olusanya, J.O.; Oluwasanu, M.M.; Omar Bali, A.; Omer, M.O.; Ong, K.L.; Onwujekwe, O.E.; Orji, A.U.; Orpana, H.M.; Ortiz, A.; Ostroff, S.M.; Otstavnov, N.; Otstavnov, S.S.; Øverland, S.; Owolabi, M.O.; P A, M.; Padubidri, J.R.; Pakhare, A.P.; Palladino, R.; Pana, A.; Panda-Jonas, S.; Pandey, A.; Park, E-K.; Parmar, P.G.K.; Pasupula, D.K.; Patel, S.K.; Paternina-Caicedo, A.J.; Pathak, A.; Pathak, M.; Patten, S.B.; Patton, G.C.; Paudel, D.; Pazoki Toroudi, H.; Peden, A.E.; Pennini, A.; Pepito, V.C.F.; Peprah, E.K.; Pe-reira, A.; Pereira, D.M.; Perico, N.; Pham, H.Q.; Phillips, M.R.; Pigott, D.M.; Pilgrim, T.; Pilz, T.M.; Pirsaheb, M.; Plana-Ripoll, O.; Plass, D.; Pokhrel, K.N.; Polibin, R.V.; Polinder, S.; Polkinghorne, K.R.; Postma, M.J.; Pourjafar, H.; Pourmalek, F.; Pourmirza Kalhori, R.; Pourshams, A.; Poznańska, A.; Prada, S.I.; Prakash, V.; Pribadi, D.R.A.; Pupillo, E.; Quazi Syed, Z.; Rabiee, M.; Rabiee, N.; Radfar, A.; Rafiee, A.; Rafiei, A.; Raggi, A.; Rahimi-Movaghar, A.; Rahman, M.A.; Rajabpour-Sanati, A.; Rajati, F.; Ramezanzadeh, K.; Ranabhat, C.L.; Rao, P.C.; Rao, S.J.; Rasella, D.; Rastogi, P.; Rathi, P.; Rawaf, D.L.; Rawaf, S.; Rawal, L.; Razo, C.; Redford, S.B.; Reiner, R.C., Jr; Reinig, N.; Reitsma, M.B.; Remuzzi, G.; Renjith, V.; Renzaho, A.M.N.; Resnikoff, S.; Rezaei, N.; Rezai, M.; Rezapour, A.; Rhinehart, P-A.; Riahi, S.M.; Ribeiro, A.L.P.; Ribeiro, D.C.; Ribeiro, D.; Rickard, J.; Roberts, N.L.S.; Roberts, S.; Robinson, S.R.; Roever, L.; Rolfe, S.; Ronfani, L.; Roshandel, G.; Roth, G.A.; Rubagotti, E.; Rumisha, S.F.; Sabour, S.; Sachdev, P.S.; Saddik, B.; Sadeghi, E.; Sadeghi, M.; Saeidi, S.; Safi, S.; Safiri, S.; Sagar, R.; Sa-hebkar, A.; Sahraian, M.A.; Sajadi, S.M.; Salahshoor, M.R.; Salamati, P.; Salehi Zahabi, S.; Salem, H.; Salem, M.R.R.; Salimzadeh, H.; Salo-mon, J.A.; Salz, I.; Samad, Z.; Samy, A.M.; Sanabria, J.; Santomauro, D.F.; Santos, I.S.; Santos, J.V.; Santric-Milicevic, M.M.; Saraswathy, S.Y.I.; Sarmiento-Suárez, R.; Sarrafzadegan, N.; Sartorius, B.; Sarveazad, A.; Sathian, B.; Sathish, T.; Sattin, D.; Sbarra, A.N.; Schaeffer, L.E.; Schiavolin, S.; Schmidt, M.I.; Schutte, A.E.; Schwebel, D.C.; Schwendicke, F.; Senbeta, A.M.; Senthilkumaran, S.; Sepanlou, S.G.; Shackel-ford, K.A.; Shadid, J.; Shahabi, S.; Shaheen, A.A.; Shaikh, M.A.; Shalash, A.S.; Shams-Beyranvand, M.; Shamsizadeh, M.; Shannawaz, M.; Sharafi, K.; Sharara, F.; Sheena, B.S.; Sheikhtaheri, A.; Shetty, R.S.; Shibuya, K.; Shiferaw, W.S.; Shigematsu, M.; Shin, J.I.; Shiri, R.; Shirkoohi, R.; Shrime, M.G.; Shuval, K.; Siabani, S.; Sigfusdottir, I.D.; Sigurvinsdottir, R.; Silva, J.P.; Simpson, K.E.; Singh, A.; Singh, J.A.; Skiadaresi, E.; Skou, S.T.; Skryabin, V.Y.; Sobngwi, E.; Sokhan, A.; Soltani, S.; Sorensen, R.J.D.; Soriano, J.B.; Sorrie, M.B.; Soyiri, I.N.; Sreeramareddy, C.T.; Stanaway, J.D.; Stark, B.A.; Ştefan, S.C.; Stein, C.; Steiner, C.; Steiner, T.J.; Stokes, M.A.; Stovner, L.J.; Stubbs, J.L.; Sudaryanto, A.; Sufiyan, M.B.; Sulo, G.; Sultan, I.; Sykes, B.L.; Sylte, D.O.; Szócska, M.; Tabarés-Seisdedos, R.; Tabb, K.M.; Tadakamadla, S.K.; Taherkhani, A.; Tajdini, M.; Takahashi, K.; Taveira, N.; Teagle, W.L.; Teame, H.; Tehrani-Banihashemi, A.; Teklehaimanot, B.F.; Ter-rason, S.; Tessema, Z.T.; Thankappan, K.R.; Thomson, A.M.; Tohidinik, H.R.; Tonelli, M.; Topor-Madry, R.; Torre, A.E.; Touvier, M.; To-vani-Palone, M.R.R.; Tran, B.X.; Travillian, R.; Troeger, C.E.; Truelsen, T.C.; Tsai, A.C.; Tsatsakis, A.; Tudor Car, L.; Tyrovolas, S.; Uddin, R.; Ullah, S.; Undurraga, E.A.; Unnikrishnan, B.; Vacante, M.; Vakilian, A.; Valdez, P.R.; Varughese, S.; Vasankari, T.J.; Vasseghian, Y.; Venketasubramanian, N.; Violante, F.S.; Vlassov, V.; Vollset, S.E.; Vongpradith, A.; Vukovic, A.; Vukovic, R.; Waheed, Y.; Walters, M.K.; Wang, J.; Wang, Y.; Wang, Y-P.; Ward, J.L.; Watson, A.; Wei, J.; Weintraub, R.G.; Weiss, D.J.; Weiss, J.; Westerman, R.; Whisnant, J.L.; Whiteford, H.A.; Wiangkham, T.; Wiens, K.E.; Wijeratne, T.; Wilner, L.B.; Wilson, S.; Wojtyniak, B.; Wolfe, C.D.A.; Wool, E.E.; Wu, A-M.; Wulf Hanson, S.; Wunrow, H.Y.; Xu, G.; Xu, R.; Yadgir, S.; Yahyazadeh Jabbari, S.H.; Yamagishi, K.; Yaminfirooz, M.; Yano, Y.; Yaya, S.; Yazdi-Feyzabadi, V.; Yearwood, J.A.; Yeheyis, T.Y.; Yeshitila, Y.G.; Yip, P.; Yonemoto, N.; Yoon, S-J.; Yoosefi Lebni, J.; Younis, M.Z.; Younker, T.P.; Yousefi, Z.; Yousefifard, M.; Yousefinezhadi, T.; Yousuf, A.Y.; Yu, C.; Yusefzadeh, H.; Zahirian Moghadam, T.; Zaki, L.; Zaman, S.B.; Zamani, M.; Zamanian, M.; Zandian, H.; Zangeneh, A.; Zastrozhin, M.S.; Zewdie, K.A.; Zhang, Y.; Zhang, Z-J.; Zhao, J.T.; Zhao, Y.; Zheng, P.; Zhou, M.; Ziapour, A.; Zimsen, S.R.M.; Naghavi, M.; Murray, C.J.L. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the global burden of disease study 2019. Lancet, 2020, 396(10258), 1204-1222.
[http://dx.doi.org/10.1016/S0140-6736(20)30925-9] [PMID: 33069326]
[3]
Kennedy, S.H.; Lam, R.W.; McIntyre, R.S.; Tourjman, S.V.; Bhat, V.; Blier, P.; Hasnain, M.; Jollant, F.; Levitt, A.J.; MacQueen, G.M.; McIn-erney, S.J.; McIntosh, D.; Milev, R.V.; Müller, D.J.; Parikh, S.V.; Pearson, N.L.; Ravindran, A.V.; Uher, R. Canadian network for mood and anxiety treatments (canmat) 2016 clinical guidelines for the management of adults with major depressive disorder. Can. J. Psychiatry, 2016, 61(9), 540-560.
[http://dx.doi.org/10.1177/0706743716659417] [PMID: 27486148]
[4]
Zhao, Q.; Fu, B.; Lyu, N.; Xu, X.; Huang, G.; Tan, Y.; Xu, X.; Zhang, X.; Wang, X.; Wang, Z.; Li, K.; Hu, Z.; Li, H.; He, H.; Li, S.; Zhao, J.; He, R.; Guo, H.; Li, Y.; Li, L.; Yang, C.; Zou, S.; Wei, B.; Wang, W.; Chen, C.; Lu, Z.; He, S.; Wang, Q.; Zhao, J.; Pan, X.; Pan, Z.; Li, J.; Wang, G. A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder. J. Affect. Disord., 2023, 329, 72-80.
[http://dx.doi.org/10.1016/j.jad.2023.02.067] [PMID: 36813043]
[5]
Wang, G.; Xiao, L.; Ren, H.; Simonsen, K.; Ma, J.; Xu, X.; Guo, P.; Wang, Z.; Bai, L.; Heldbo Reines, E.; Hammer-Helmich, L. Effectiveness and safety of vortioxetine for major depressive disorder in real-world clinical practice: Results from the single-arm relieve china study. Neuropsychiatr. Dis. Treat., 2022, 18, 1939-1950.
[http://dx.doi.org/10.2147/NDT.S358253] [PMID: 36065389]
[6]
Wang, G.; Han, C.; Liu, C.Y.; Chan, S.; Kato, T.; Tan, W.; Zhang, L.; Feng, Y.; Ng, C.H. Management of treatment-resistant depression in real-world clinical practice settings across asia. Neuropsychiatr. Dis. Treat., 2020, 16, 2943-2959.
[http://dx.doi.org/10.2147/NDT.S264813] [PMID: 33299316]
[7]
Warden, D.; Rush, A.J.; Trivedi, M.H.; Fava, M.; Wisniewski, S.R. The STAR*D project results: A comprehensive review of findings. Curr. Psychiatry Rep., 2007, 9(6), 449-459.
[http://dx.doi.org/10.1007/s11920-007-0061-3] [PMID: 18221624]
[8]
Ren, F.; Ma, Y.; Zhu, X.; Guo, R.; Wang, J.; He, L. Pharmacogenetic association of bi- and triallelic polymorphisms of SLC6A4 with antide-pressant response in major depressive disorder. J. Affect. Disord., 2020, 273, 254-264.
[http://dx.doi.org/10.1016/j.jad.2020.04.058] [PMID: 32421611]
[9]
Brignone, M.; Diamand, F.; Painchault, C.; Takyar, S. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepres-sants in patients with major depressive disorder. Curr. Med. Res. Opin., 2016, 32(2), 351-366.
[http://dx.doi.org/10.1185/03007995.2015.1128404] [PMID: 26637048]
[10]
Gillett, G.; Tomlinson, A.; Efthimiou, O.; Cipriani, A. Predicting treatment effects in unipolar depression: A meta-review. Pharmacol. Ther., 2020, 212, 107557.
[http://dx.doi.org/10.1016/j.pharmthera.2020.107557] [PMID: 32437828]
[11]
Perlman, K.; Benrimoh, D.; Israel, S.; Rollins, C.; Brown, E.; Tunteng, J.F.; You, R.; You, E.; Tanguay-Sela, M.; Snook, E.; Miresco, M.; Berlim, M.T. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. J. Affect. Disord., 2019, 243, 503-515.
[http://dx.doi.org/10.1016/j.jad.2018.09.067] [PMID: 30286415]
[12]
Lauschke, V.M.; Zhou, Y.; Ingelman-Sundberg, M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol. Ther., 2019, 197, 122-152.
[http://dx.doi.org/10.1016/j.pharmthera.2019.01.002] [PMID: 30677473]
[13]
Lauschke, V.M.; Ingelman-Sundberg, M. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Se-quencing. Eur. J. Pharm. Sci., 2019, 130, 65-77.
[http://dx.doi.org/10.1016/j.ejps.2019.01.024] [PMID: 30684656]
[14]
Tansey, K.E.; Guipponi, M.; Hu, X.; Domenici, E.; Lewis, G.; Malafosse, A.; Wendland, J.R.; Lewis, C.M.; McGuffin, P.; Uher, R. Contribu-tion of common genetic variants to antidepressant response. Biol. Psychiatry, 2013, 73(7), 679-682.
[http://dx.doi.org/10.1016/j.biopsych.2012.10.030] [PMID: 23237317]
[15]
Milosavljevic, F.; Bukvic, N.; Pavlovic, Z.; Miljevic, C.; Pešic, V.; Molden, E.; Ingelman-Sundberg, M.; Leucht, S.; Jukic, M.M. Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure. JAMA Psychiatry, 2021, 78(3), 270-280.
[http://dx.doi.org/10.1001/jamapsychiatry.2020.3643] [PMID: 33237321]
[16]
Culverhouse, R.C.; Saccone, N.L.; Horton, A.C.; Ma, Y.; Anstey, K.J.; Banaschewski, T.; Burmeister, M.; Cohen-Woods, S.; Etain, B.; Fisher, H.L.; Goldman, N.; Guillaume, S.; Horwood, J.; Juhasz, G.; Lester, K.J.; Mandelli, L.; Middeldorp, C.M.; Olié, E.; Villafuerte, S.; Air, T.M.; Araya, R.; Bowes, L.; Burns, R.; Byrne, E.M.; Coffey, C.; Coventry, W.L.; Gawronski, K A B.; Glei, D.; Hatzimanolis, A.; Hottenga, J-J.; Jaussent, I.; Jawahar, C.; Jennen-Steinmetz, C.; Kramer, J.R.; Lajnef, M.; Little, K.; zu Schwabedissen, H.M.; Nauck, M.; Nederhof, E.; Petschner, P.; Peyrot, W.J.; Schwahn, C.; Sinnamon, G.; Stacey, D.; Tian, Y.; Toben, C.; Van der Auwera, S.; Wainwright, N.; Wang, J-C.; Wil-lemsen, G.; Anderson, I.M.; Arolt, V.; Åslund, C.; Bagdy, G.; Baune, B.T.; Bellivier, F.; Boomsma, D.I.; Courtet, P.; Dannlowski, U.; de Geus, E.J.C.; Deakin, J F W.; Easteal, S.; Eley, T.; Fergusson, D.M.; Goate, A.M.; Gonda, X.; Grabe, H.J.; Holzman, C.; Johnson, E.O.; Ken-nedy, M.; Laucht, M.; Martin, N.G.; Munafò, M.R.; Nilsson, K.W.; Oldehinkel, A.J.; Olsson, C.A.; Ormel, J.; Otte, C.; Patton, G.C.; Penninx, B.W.J.H.; Ritchie, K.; Sarchiapone, M.; Scheid, J.M.; Serretti, A.; Smit, J.H.; Stefanis, N.C.; Surtees, P.G.; Völzke, H.; Weinstein, M.; Whooley, M.; Nurnberger, J.I., Jr; Breslau, N.; Bierut, L.J. Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. Mol. Psychiatry, 2018, 23(1), 133-142.
[http://dx.doi.org/10.1038/mp.2017.44] [PMID: 28373689]
[17]
Hiemke, C.; Bergemann, N.; Clement, H.W.; Conca, A.; Deckert, J.; Domschke, K.; Eckermann, G.; Egberts, K.; Gerlach, M.; Greiner, C.; Gründer, G.; Haen, E.; Havemann-Reinecke, U.; Hefner, G.; Helmer, R.; Janssen, G.; Jaquenoud, E.; Laux, G.; Messer, T.; Mössner, R.; Müller, M.J.; Paulzen, M.; Pfuhlmann, B.; Riederer, P.; Saria, A.; Schoppek, B.; Schoretsanitis, G.; Schwarz, M.; Gracia, M.S.; Stegmann, B.; Steimer, W.; Stingl, J.C.; Uhr, M.; Ulrich, S.; Unterecker, S.; Waschgler, R.; Zernig, G.; Zurek, G.; Baumann, P. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology:Update 2017. Pharmacopsychiatry, 2018, 1(1-02), 9-62.
[18]
Jukić, M.M.; Haslemo, T.; Molden, E.; Ingelman-Sundberg, M. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic fail-ure: A retrospective study based on 2,087 patients. Am. J. Psychiatry, 2018, 175(5), 463-470.
[http://dx.doi.org/10.1176/appi.ajp.2017.17050550] [PMID: 29325448]
[19]
Furukawa, T.A.; Cipriani, A.; Cowen, P.J.; Leucht, S.; Egger, M.; Salanti, G. Optimal dose of selective serotonin reuptake inhibitors, venlafax-ine, and mirtazapine in major depression: A systematic review and dose-response meta-analysis. Focus Am. Psychiatr. Publ., 2020, 18(2), 211-219.
[http://dx.doi.org/10.1176/appi.focus.18204] [PMID: 33343239]
[20]
Fabbri, C.; Zohar, J.; Serretti, A. Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2018, 86, 36-44.
[http://dx.doi.org/10.1016/j.pnpbp.2018.05.007] [PMID: 29777729]
[21]
Table of pharmacogenomic biomarkers in drug labeling. 2022. Avaialble from: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
[22]
Taylor, C.; Crosby, I.; Yip, V.; Maguire, P.; Pirmohamed, M.; Turner, R.M. A review of the important role of CYP2D6 in pharmacogenomics. Genes, 2020, 11(11), 1295.
[http://dx.doi.org/10.3390/genes11111295] [PMID: 33143137]
[23]
Zemanova, N.; Anzenbacher, P.; Anzenbacherova, E. The role of cytochromes P450 in the metabolism of selected antidepressants and anxio-lytics under psychological stress. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2022, 166(2), 140-149.
[http://dx.doi.org/10.5507/bp.2022.019] [PMID: 35438085]
[24]
Oz, M.D.; Baskak, B.; Uckun, Z.; Artun, N.Y.; Ozdemir, H.; Ozel, T.K.; Ozguven, H.D.; Suzen, H.S. Association between serotonin 2A recep-tor (HTR2A), serotonin transporter (SLC6A4) and brain-derived neurotrophic factor (BDNF) gene polymorphisms and citalopram/sertraline induced sexual dysfunction in MDD patients. Pharmacogenomics J., 2020, 20(3), 443-450.
[http://dx.doi.org/10.1038/s41397-019-0127-8] [PMID: 31792367]
[25]
van der Schans, J.; Hak, E.; Postma, M.; Breuning, L.; Brouwers, J.R.B.J.; Ditters, K.; Jansen, P.A.F.; Kok, R.M.; Maring, J.G.; van Marum, R.; Mulder, H.; Nanninga, J.; Oude Voshaar, R.C.; Risselada, A.J.; Vleugel, L.; Stek, M.; van Schaik, R.H.N.; Berm, E.J.J.; Wilffert, B. Effects of pharmacogenetic screening for cyp2d6 among elderly starting therapy with nortriptyline or venlafaxine. J. Clin. Psychopharmacol., 2019, 39(6), 583-590.
[http://dx.doi.org/10.1097/JCP.0000000000001129] [PMID: 31688392]
[26]
Thürmann, P.A. Pharmacodynamics and pharmacokinetics in older adults. Curr. Opin. Anaesthesiol., 2020, 33(1), 109-113.
[http://dx.doi.org/10.1097/ACO.0000000000000814] [PMID: 31789903]
[27]
Ahmed, A.T.; Biernacka, J.M.; Jenkins, G.; Rush, A.J.; Shinozaki, G.; Veldic, M.; Kung, S.; Bobo, W.V.; Hall-Flavin, D.K.; Weinshilboum, R.M.; Wang, L.; Frye, M.A. Pharmacokinetic-pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram/escitalopram treatment failure. J. Affect. Disord., 2019, 246, 62-68.
[http://dx.doi.org/10.1016/j.jad.2018.12.021] [PMID: 30578947]
[28]
Rahikainen, A.L.; Vauhkonen, P.; Pett, H.; Palo, J.U.; Haukka, J.; Ojanperä, I.; Niemi, M.; Sajantila, A. Completed suicides of citalopram users-the role of CYP genotypes and adverse drug interactions. Int. J. Legal Med., 2019, 133(2), 353-363.
[http://dx.doi.org/10.1007/s00414-018-1927-0] [PMID: 30173302]
[29]
Aldrich, S.L.; Poweleit, E.A.; Prows, C.A.; Martin, L.J.; Strawn, J.R.; Ramsey, L.B. Influence of CYP2C19 metabolizer status on escital-opram/citalopram tolerability and response in youth with anxiety and depressive disorders. Front. Pharmacol., 2019, 10, 99.
[http://dx.doi.org/10.3389/fphar.2019.00099] [PMID: 30837874]
[30]
Claudio-Campos, K.; Padrón, A.; Jerkins, G.; Nainaparampil, J.; Nelson, R.; Martin, A.; Wiisanen, K.; Smith, D.M.; Strekalova, Y.; Marsiske, M.; Cicali, E.J.; Cavallari, L.H.; Mathews, C.A. Acceptability, feasibility, and utility of integrating pharmacogenetic testing into a child psychi-atry clinic. Clin. Transl. Sci., 2021, 14(2), 589-598.
[http://dx.doi.org/10.1111/cts.12914] [PMID: 33166056]
[31]
Saiz-Rodríguez, M.; Belmonte, C.; Román, M.; Ochoa, D.; Koller, D.; Talegón, M.; Ovejero-Benito, M.C.; López-Rodríguez, R.; Cabaleiro, T.; Abad-Santos, F. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers. Basic Clin. Pharmacol. Toxicol., 2018, 122(5), 501-511.
[http://dx.doi.org/10.1111/bcpt.12938] [PMID: 29136336]
[32]
Kharasch, E.D.; Crafford, A. Common polymorphisms of cyp2b6 influence stereoselective bupropion disposition. Clin. Pharmacol. Ther., 2019, 105(1), 142-152.
[http://dx.doi.org/10.1002/cpt.1116] [PMID: 29756345]
[33]
Serretti, A.; Calati, R.; Massat, I.; Linotte, S.; Kasper, S.; Lecrubier, Y.; Sens-Espel, R.; Bollen, J.; Zohar, J.; Berlo, J.; Lienard, P.; De Ronchi, D.; Mendlewicz, J.; Souery, D. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and re-mission in a sample of depressive patients. Int. Clin. Psychopharmacol., 2009, 24(5), 250-256.
[http://dx.doi.org/10.1097/YIC.0b013e32832e5b0d] [PMID: 19593158]
[34]
Zhu, Y.; Zhang, N.; Ren, D.; Bi, Y.; Xu, F.; Niu, W.; Sun, Q.; Guo, Z.; Yuan, R.; Yuan, F.; Wu, X.; Cao, Y.; Yang, F.; Wang, L.; Du, L.; Li, W.; Xu, Y.; Li, X.; Zhu, L.; He, L.; Shi, L.; He, G.; Yu, T. CYP1A2 genetic polymorphism is associated with treatment remission to antide-pressant venlafaxine in han chinese population. Clin. Neuropharmacol., 2019, 42(2), 32-36.
[http://dx.doi.org/10.1097/WNF.0000000000000322] [PMID: 30875344]
[35]
Elias, E.; Zhang, A.Y.; Manners, M.T. Novel pharmacological approaches to the treatment of depression. Life, 2022, 12(2), 196.
[http://dx.doi.org/10.3390/life12020196] [PMID: 35207483]
[36]
He, T.; Wu, Z.; Zhang, X.; Liu, H.; Wang, Y.; Jiang, R.; Liu, C.; Hashimoto, K.; Yang, C. A bibliometric analysis of research on the role of BDNF in depression and treatment. Biomolecules, 2022, 12(10), 1464.
[http://dx.doi.org/10.3390/biom12101464] [PMID: 36291673]
[37]
Stachowicz, K.; Sowa-Kućma, M. The treatment of depression: Searching for new ideas. Front. Pharmacol., 2022, 13, 988648.
[http://dx.doi.org/10.3389/fphar.2022.988648] [PMID: 36278184]
[38]
Jameson, A.; Fylan, B.; Bristow, G.C.; Sagoo, G.S.; Dalton, C.; Cardno, A.; Sohal, J.; McLean, S.L. What are the barriers and enablers to the implementation of pharmacogenetic testing in mental health care settings? Front. Genet., 2021, 12, 740216.
[http://dx.doi.org/10.3389/fgene.2021.740216] [PMID: 34630531]
[39]
Stein, K.; Maruf, A.A.; Müller, D.J.; Bishop, J.R.; Bousman, C.A. Serotonin transporter genetic variation and antidepressant response and tolerability: A systematic review and meta-analysis. J. Pers. Med., 2021, 11(12), 1334.
[http://dx.doi.org/10.3390/jpm11121334] [PMID: 34945806]
[40]
Lesch, K.P.; Bengel, D.; Heils, A.; Sabol, S.Z.; Greenberg, B.D.; Petri, S.; Benjamin, J.; Müller, C.R.; Hamer, D.H.; Murphy, D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 1996, 274(5292), 1527-1531.
[http://dx.doi.org/10.1126/science.274.5292.1527] [PMID: 8929413]
[41]
Kao, W.T.; Chang, C.L.; Lung, F.W. 5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial. J. Affect. Disord., 2018, 238, 597-608.
[http://dx.doi.org/10.1016/j.jad.2018.06.035] [PMID: 29957477]
[42]
Gulfishan, S.; Halder, S.; Kar, R.; Srivastava, S.; Gupta, R. Association of serotonin transporter gene polymorphism with efficacy of the anti-depressant drugs sertraline and mirtazapine in newly diagnosed patients with major depressive disorders. Hum. Psychopharmacol., 2022, 37(4), e2833.
[http://dx.doi.org/10.1002/hup.2833] [PMID: 35089613]
[43]
Poweleit, E.A.; Aldrich, S.L.; Martin, L.J.; Hahn, D.; Strawn, J.R.; Ramsey, L.B. Pharmacogenetics of sertraline tolerability and response in pediatric anxiety and depressive disorders. J. Child Adolesc. Psychopharmacol., 2019, 29(5), 348-361.
[http://dx.doi.org/10.1089/cap.2019.0017] [PMID: 31066578]
[44]
Brunoni, A.R.; Carracedo, A.; Amigo, O.M.; Pellicer, A.L.; Talib, L.; Carvalho, A.F.; Lotufo, P.A.; Benseñor, I.M.; Gattaz, W.; Cappi, C. As-sociation of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a dou-ble-blind, placebo-controlled trial. Br. J. Psychiatry, 2020, 42(2), 128-135.
[http://dx.doi.org/10.1590/1516-4446-2019-0620] [PMID: 31721892]
[45]
Camarena, B.; Álvarez-Icaza, D.; Hernández, S.; Aguilar, A.; Münch, L.; Martínez, C.; Becerra-Palars, C. Association study between serotonin transporter gene and fluoxetine response in mexican patients with major depressive disorder. Clin. Neuropharmacol., 2019, 42(1), 9-13.
[http://dx.doi.org/10.1097/WNF.0000000000000315] [PMID: 30520759]
[46]
Le François, B.; Czesak, M.; Steubl, D.; Albert, P.R. Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology, 2008, 55(6), 977-985.
[http://dx.doi.org/10.1016/j.neuropharm.2008.06.046] [PMID: 18639564]
[47]
Houston, J.P.; Zou, W.; Aris, V.; Fijal, B.; Chen, P.; Heinloth, A.N.; Martinez, J. Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder. Psychiatry Res., 2012, 200(1), 63-65.
[http://dx.doi.org/10.1016/j.psychres.2012.06.002] [PMID: 22727709]
[48]
Zhao, X.; Huang, Y.; Li, J.; Ma, H.; Jin, Q.; Wang, Y.; Wu, L.; Zhu, G. Association between the 5-HT1A receptor gene polymorphism (rs6295) and antidepressants. Int. Clin. Psychopharmacol., 2012, 27(6), 1.
[http://dx.doi.org/10.1097/YIC.0b013e32835818bf] [PMID: 22890315]
[49]
Ochi, T.; Vyalova, N.M.; Losenkov, I.S.; Paderina, D.Z.; Pozhidaev, I.V.; Loonen, A.J.M.; Simutkin, G.G.; Bokhan, N.A.; Ivanova, S.A.; Wilffert, B. Limited associations between 5-HT receptor gene polymorphisms and treatment response in antidepressant treatment-free pa-tients with depression. Front. Pharmacol., 2019, 10, 1462.
[http://dx.doi.org/10.3389/fphar.2019.01462] [PMID: 31956308]
[50]
Ramesh, V.; Venkatesan, V.; Ramasamy, B. Role of serotonin transporter and receptor gene polymorphisms in treatment response to selec-tive serotonin reuptake inhibitors in major depressive disorder. Hum. Psychopharmacol., 2022, 37(4), e2830.
[http://dx.doi.org/10.1002/hup.2830] [PMID: 34994008]
[51]
Badamasi, I.M.; Lye, M.S.; Ibrahim, N.; Abdul Razaq, N.A.; Ling, K.H.; Stanslas, J. Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder. Pharmacogenomics J., 2021, 21(4), 498-509.
[http://dx.doi.org/10.1038/s41397-021-00228-6] [PMID: 33731884]
[52]
Yuan, R.; Yuan, F.; Ren, D.; Zhu, Y.; Bi, Y.; Hu, J.; Guo, Z.; Xu, F.; Niu, W.; Wu, X.; Cao, Y.; Yang, F.; Wang, L.; Li, W.; Xu, Y.; He, L.; Yu, T.; He, G.; Li, X. HTR1A and HTR2A variants may not predict venlafaxine treatment response in China Han population with major depres-sive disorder. Psychiatry Res., 2018, 270, 1179-1180.
[http://dx.doi.org/10.1016/j.psychres.2018.10.038] [PMID: 30366640]
[53]
Alizadeh, N.; Nosrat, N.; Jahani, Z.; Ahmadiani, A.; Asadi, S.; Shams, J. Association of HTR1A gene polymorphisms with obsessive–compulsive disorder and its treatment response: The influence of sex and clinical characteristics. Int. J. Neurosci., 2019, 129(3), 264-272.
[http://dx.doi.org/10.1080/00207454.2018.1526799] [PMID: 30232922]
[54]
Klengel, T.; Binder, E.B. Gene × environment interactions in the prediction of response to antidepressant treatment. Int. J. Neuropsychopharmacol., 2013, 16(3), 701-711.
[http://dx.doi.org/10.1017/S1461145712001459] [PMID: 23237009]
[55]
Meyer, J.H.; Kapur, S.; Eisfeld, B.; Brown, G.M.; Houle, S.; DaSilva, J.; Wilson, A.A.; Rafi-Tari, S.; Mayberg, H.S.; Kennedy, S.H. The effect of paroxetine on 5-HT(2A) receptors in depression: An [(18)F]setoperone PET imaging study. Am. J. Psychiatry, 2001, 158(1), 78-85.
[http://dx.doi.org/10.1176/appi.ajp.158.1.78] [PMID: 11136637]
[56]
Fabbri, C.; Hosak, L.; Mössner, R.; Giegling, I.; Mandelli, L.; Bellivier, F.; Claes, S.; Collier, D.A.; Corrales, A.; Delisi, L.E.; Gallo, C.; Gill, M.; Kennedy, J.L.; Leboyer, M.; Lisoway, A.; Maier, W.; Marquez, M.; Massat, I.; Mors, O.; Muglia, P.; Nöthen, M.M.; O’Donovan, M.C.; Ospina-Duque, J.; Propping, P.; Shi, Y.; St Clair, D.; Thibaut, F.; Cichon, S.; Mendlewicz, J.; Rujescu, D.; Serretti, A. Consensus paper of the WFSBP task force on genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World J. Biol. Psychiatry, 2017, 18(1), 5-28.
[http://dx.doi.org/10.1080/15622975.2016.1208843] [PMID: 27603714]
[57]
Gassó, P.; Blázquez, A.; Rodríguez, N.; Boloc, D.; Torres, T.; Mas, S.; Lafuente, A.; Lázaro, L. Further support for the involvement of genetic variants related to the serotonergic pathway in the antidepressant response in children and adolescents after a 12-month follow-up: Impact of the HTR2A rs7997012 Polymorphism. J. Child Adolesc. Psychopharmacol., 2018, 28(10), 711-718.
[http://dx.doi.org/10.1089/cap.2018.0004] [PMID: 29975559]
[58]
Demirbugen Oz, M.; Uckun, Z.; Yuce-Artun, N.; Baskak, B.; Ozdemir, H.; Kizil Ozel, T.; Devrimci Ozguven, H.; Suzen, H.S. The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients. Hum. Psychopharmacol., 2018, 33(5), e2673.
[http://dx.doi.org/10.1002/hup.2673] [PMID: 30221791]
[59]
Duman, R.S.; Voleti, B. Signaling pathways underlying the pathophysiology and treatment of depression: Novel mechanisms for rapid-acting agents. Trends Neurosci., 2012, 35(1), 47-56.
[http://dx.doi.org/10.1016/j.tins.2011.11.004] [PMID: 22217452]
[60]
Fabbri, C.; Corponi, F.; Albani, D.; Raimondi, I.; Forloni, G.; Schruers, K.; Kasper, S.; Kautzky, A.; Zohar, J.; Souery, D.; Montgomery, S.; Cristalli, C.P.; Mantovani, V.; Mendlewicz, J.; Serretti, A. Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2018, 81, 203-210.
[http://dx.doi.org/10.1016/j.pnpbp.2017.10.005] [PMID: 28989100]
[61]
Niitsu, T.; Fabbri, C.; Bentini, F.; Serretti, A. Pharmacogenetics in major depression: A comprehensive meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 45, 183-194.
[http://dx.doi.org/10.1016/j.pnpbp.2013.05.011] [PMID: 23733030]
[62]
Ising, M.; Maccarrone, G.; Brückl, T.; Scheuer, S.; Hennings, J.; Holsboer, F.; Turck, C.; Uhr, M.; Lucae, S. FKBP5 gene expression predicts antidepressant treatment outcome in depression. Int. J. Mol. Sci., 2019, 20(3), 485.
[http://dx.doi.org/10.3390/ijms20030485] [PMID: 30678080]
[63]
Yang, C.; Li, S.; Ma, Y.; Chen, B.; Li, M.; Bosker, F.J.; Li, J.; Nolte, I.M. Lack of association of FKBP5 SNPs and haplotypes with suscepti-bility and treatment response phenotypes in han chinese with major depressive disorder. Medicine, 2021, 100(36), e26983.
[http://dx.doi.org/10.1097/MD.0000000000026983] [PMID: 34516490]
[64]
Nobile, B.; Ramoz, N.; Jaussent, I.; Dubois, J.; Guillaume, S.; Gorwood, P.; Courtet, P. Polymorphisms of stress pathway genes and emer-gence of suicidal ideation at antidepressant treatment onset. Transl. Psychiatry, 2020, 10(1), 320.
[http://dx.doi.org/10.1038/s41398-020-01003-0] [PMID: 32952155]
[65]
Tiwari, S.; Qi, L.; Wong, J.; Han, Z. Association of peripheral manifestation of brain‐derived neurotrophic factor with depression: A meta‐analysis. Brain Behav., 2022, 12(6), e32581.
[http://dx.doi.org/10.1002/brb3.2581] [PMID: 35510613]
[66]
Cocchi, E.; Fabbri, C.; Han, C.; Lee, S.J.; Patkar, A.A.; Masand, P.S.; Pae, C.U.; Serretti, A. Genome-wide association study of antidepressant response: Involvement of the inorganic cation transmembrane transporter activity pathway. BMC Psychiatry, 2016, 16(1), 106.
[http://dx.doi.org/10.1186/s12888-016-0813-x] [PMID: 27091189]
[67]
Chen, M.H.; Kao, C.F.; Tsai, S.J.; Li, C.T.; Lin, W.C.; Hong, C.J.; Bai, Y.M.; Tu, P.C.; Su, T.P. Treatment response to low-dose ketamine infusion for treatment-resistant depression: A gene-based genome-wide association study. Genomics, 2021, 113(2), 507-514.
[http://dx.doi.org/10.1016/j.ygeno.2020.12.030] [PMID: 33370585]
[68]
Chen, M.H.; Lin, W.C.; Wu, H.J.; Cheng, C.M.; Li, C.T.; Hong, C.J.; Tu, P.C.; Bai, Y.M.; Tsai, S.J.; Su, T.P. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). J. Affect. Disord., 2019, 251, 162-169.
[http://dx.doi.org/10.1016/j.jad.2019.03.075] [PMID: 30925267]
[69]
Ochi, T.; Vyalova, N.M.; Losenkov, I.S.; Levchuk, L.A.; Osmanova, D.Z.; Mikhalitskaya, E.V.; Loonen, A.J.M.; Bosker, F.J.; Simutkin, G.G.; Bokhan, N.A.; Wilffert, B.; Ivanova, S.A. Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients. J. Affect. Disord., 2019, 259, 432-439.
[http://dx.doi.org/10.1016/j.jad.2019.08.058] [PMID: 31611000]
[70]
Martin, S.; Colle, R.; El Asmar, K.; Rigal, A.; Vievard, A.; Feve, B.; Becquemont, L.; Verstuyft, C.; Corruble, E. HOMA-IR increase after antidepressant treatment in depressed patients with the Met allele of the Val66Met BDNF genetic polymorphism. Psychol. Med., 2019, 49(14), 2364-2369.
[http://dx.doi.org/10.1017/S0033291718003240] [PMID: 30526722]
[71]
Zheng, X.; Fu, Z.; Chen, X.; Wang, M.; Zhu, R. Effects of ABCB1 gene polymorphism on the efficacy of antidepressant drugs. Medicine, 2021, 100(28), e26411.
[http://dx.doi.org/10.1097/MD.0000000000026411] [PMID: 34260525]
[72]
Magalhães, P.; Alves, G.; Fortuna, A.; Llerena, A.; Falcão, A. Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-)genetic factors. Exp. Clin. Psychopharmacol., 2020, 28(5), 589-600.
[http://dx.doi.org/10.1037/pha0000334] [PMID: 31750687]
[73]
Rahikainen, A.L.; Palo, J.U.; Haukka, J.; Sajantila, A. Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T–2677T–3435T as a candidate predisposing factor behind adverse drug reactions in females. Pharmacogenet. Genomics, 2018, 28(4), 99-106.
[http://dx.doi.org/10.1097/FPC.0000000000000328] [PMID: 29481489]
[74]
Simoons, M.; Mulder, H.; Appeldoorn, J.T.Y.; Risselada, A.J.; Schene, A.H.; van Schaik, R.H.N.; van Roon, E.N.; Ruhé, E.G. Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depres-sive disorder. Psychiatr. Genet., 2020, 30(1), 19-29.
[http://dx.doi.org/10.1097/YPG.0000000000000244] [PMID: 31634334]
[75]
Geers, L.M.; Ochi, T.; Vyalova, N.M.; Losenkov, I.S.; Paderina, D.Z.; Pozhidaev, I.V.; Simutkin, G.G.; Bokhan, N.A.; Wilffert, B.; Touw, D.J.; Loonen, A.J.M.; Ivanova, S.A. Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treat-ment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design. Hum. Psychopharmacol., 2022, 37(3), e2826.
[http://dx.doi.org/10.1002/hup.2826] [PMID: 34788473]
[76]
Pronk, A.C.; Seppala, L.J.; Trajanoska, K.; Stringa, N.; van de Loo, B.; de Groot, L.C.P.G.M.; van Schoor, N.M.; Koskeridis, F.; Mar-kozannes, G.; Ntzani, E.; Uitterlinden, A.G.; Rivadeneira, F.; Stricker, B.H.; van der Velde, N. Candidate genetic variants and antidepressant-related fall risk in middle-aged and older adults. PLoS One, 2022, 17(4), e0266590.
[http://dx.doi.org/10.1371/journal.pone.0266590] [PMID: 35421149]
[77]
Corponi, F.; Fabbri, C.; Boriani, G.; Diemberger, I.; Albani, D.; Forloni, G.; Serretti, A.; Corrected, Q.T. Corrected QT interval prolongation in psychopharmacological treatment and its modulation by genetic variation. Neuropsychobiology, 2019, 77(2), 67-72.
[http://dx.doi.org/10.1159/000493400] [PMID: 30544110]
[78]
Gu, M.; Li, A.; Mak, W.; Dong, F.; Xu, N.; Zhang, J.; Shi, Y.; Zheng, N.; Tang, Z.; He, Q.; Ruan, C.; Guo, W.; Xiang, X.; Wang, C.; Han, B.; Zhu, X. Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization. Front. Pharmacol., 2023, 14, 1089862.
[http://dx.doi.org/10.3389/fphar.2023.1089862] [PMID: 36744255]
[79]
Zhu, L.; Zheng, N.; Li, X.; Zhang, X. Hepatic artery and peripheral vein pharmacokinetics of raltitrexed in swine after the administration of a hepatic arterial infusion. Curr. Drug Metab., 2019, 20(7), 601-608.
[http://dx.doi.org/10.2174/1389200220666190618100847] [PMID: 31237202]
[80]
Zheng, N.; Lian, B.; Xu, G.; Liu, X.; Li, X.; Ji, J. Development of a subcellular semimechanism-based pharmacokinetic/pharmacodynamic model to characterize paclitaxel effects delivered by polymeric micelles. J. Pharm. Sci., 2019, 108(1), 725-731.
[http://dx.doi.org/10.1016/j.xphs.2018.10.062] [PMID: 30414867]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy